What question did this study set out to answer?

To investigate the effectiveness of micro-RNA-371a-3p as a biomarker for predicting recurrence in clinical stage I testicular cancer.

July 13, 2026Open Access

View Full Paper

Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular Cancer

RMRichard S. MatulewiczMemorial Sloan Kettering Cancer Center AKAndrea KneževićMemorial Sloan Kettering Cancer Center ALAdam LevinMemorial Sloan Kettering Cancer Center

Key Points

To investigate the effectiveness of micro-RNA-371a-3p as a biomarker for predicting recurrence in clinical stage I testicular cancer.
Utilized micro-RNA-371a-3p measurement
Analyzed recurrence rates in clinical stage I testicular cancer patients
Employed statistical analysis to assess predictive accuracy.
Micro-RNA-371a-3p was significantly associated with recurrence risk in patients (specific metrics not provided).
Higher levels of micro-RNA-371a-3p correlated with increased recurrence rates, indicating its potential as a predictive biomarker.

Abstract

Richard S Matulewicz, Andrea Knezevic, Adam Levin, Fei Ye, Darren R Feldman, Samuel A Funt; Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinic

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular Cancer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider